RR Kabel IPO Likely to List with 10-15% Premium

| Leave a Comment | IPO

The stock of RR Kabel is likely to list with a 10-15% premium over the issue price of Rs 1,035 on September 20, based on the following factors:

  • Impressive response to public issue:The RR Kabel IPO was subscribed 18.69 times during September 13-15, with major support from qualified institutional investors, high net-worth individuals, and retail investors.
  • Positive sentiment in equity market:The Indian equity market has been on a bullish run in recent months, with the Nifty50 index hitting a record high on September 16, 2023. This positive sentiment is expected to support the listing of RR Kabel.
  • Strong fundamentals: RR Kabel is a leading player in the wires and cables industry in India. The company has a strong track record of growth and profitability. It also has a healthy balance sheet.

However, the following factors may limit the upside for the stock:

  • Subdued financials: RR Kabel’s net profit declined by 11.2% in FY23, due to higher input costs and other expenses.
  • High OFS portion: The OFS portion in the RR Kabel IPO was 90%. This means that a large portion of the shares sold in the IPO were by existing shareholders. This may limit the upside for the stock in the short term.

Overall, the outlook for the RR Kabel IPO listing is positive. However, investors should be aware of the subdued financials and the high OFS portion before investing.

Additional Factors to Consider

  • Sector outlook: The wires and cables industry is expected to grow at a healthy pace in the coming years, driven by factors such as increasing urbanization, rising disposable incomes, and growing infrastructure investments. This will benefit RR Kabel.
  • Competition: RR Kabel faces competition from other established players in the wires and cables industry, such as Havells India, Polycab India, and Finolex Cables. Investors should assess RR Kabel’s competitive strengths and weaknesses before investing.
  • Management track record: RR Kabel has a management team with a strong track record. Investors should assess the management’s vision and strategy for the company before investing.


Investors should carefully consider the risks and rewards involved before investing in RR Kabel. While the overall outlook for the listing is positive, investors should be aware of the subdued financials, the high OFS portion, and the competitive landscape. Investors should also assess the company’s management team and strategy before investing.


Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Unihealth Consultancy makes tepid debut on NSE Emerge

    Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.

Leave a Reply

Your email address will not be published. Required fields are marked *